Delila Gasi Tandefelt

Plasma <i>AR</i> and abiraterone-resistant prostate cancer

Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca et al. · Science Translational Medicine · 2015 · 441 citations · Full text

Medicine, Oncology, Pharmacology +14

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani et al. · Annals of Oncology · 2017 · 269 citations · Full text

Medicine, Oncology, Pharmacology +17

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

Jean‐Sébastien Frenel, Suzanne Carreira, Jane Goodall et al. · Clinical Cancer Research · 2015 · 184 citations

Medicine, Molecular Medicine, Oncology +17

Overexpression of Prostate-Specific <i>TMPRSS2(exon 0)-ERG</i> Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer

Karin G. Hermans, Joost L. Boormans, Delila Gasi Tandefelt et al. · Clinical Cancer Research · 2009 · 89 citations · Full text

Medicine, Molecular Biology, Oncology +16

A 36-gene Signature Predicts Clinical Progression in a Subgroup of ERG-positive Prostate Cancers

Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput et al. · European Urology · 2013 · 41 citations

Medicine, Oncology, Urology +16